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Objective: To develop and validate a risk prediction model that would help individualize treatment and
improve the shared decision-making process between clinicians and patients.
Patients and Methods: Wedeveloped a risk prediction tool formortality during the ﬁrst year of dialysis based
on preeend-stage renal disease characteristics in a cohort of 35,878 US veterans with incident end-stage renal
disease who transitioned to dialysis treatment between October 1, 2007, and March 31, 2014 and then
externally validated this tool among 4284 patients in the Kaiser Permanente Southern California (KPSC) health
care system who transitioned to dialysis treatment between January 1, 2007, and September 30, 2015.
Results: To ensure model goodness of ﬁt, 2 separate models were selected for patients whose last
estimated glomerular ﬁltration rate (eGFR) before dialysis initiation was less than 15 mL/min per 1.73 m2
or 15 mL/min per 1.73 m2 or higher. Model discrimination in the internal validation cohort of veterans
resulted in C statistics of 0.71 (95% CI, 0.70-0.72) and 0.66 (95% CI, 0.65-0.67) among patients with
eGFR lower than 15 mL/min per 1.73 m2 and 15 mL/min per 1.73 m2 or higher, respectively. In the KPSC
external validation cohort, the developed risk score exhibited C statistics of 0.77 (95% CI, 0.74-0.79) in
men and 0.74 (95% CI, 0.71-0.76) in women with eGFR lower than 15 mL/min per 1.73 m2 and 0.71
(95% CI, 0.67-0.74) in men and 0.67 (95% CI, 0.62-0.72) in women with eGFR of 15 mL/min per 1.73
m2 or higher.
Conclusion: A new risk prediction tool for mortality during the ﬁrst year after transition to dialysis
(available at www.DialysisScore.com) was developed in the large national Veterans Affairs cohort and
validated with good performance in the racially, ethnically, and gender diverse KPSC cohort. This risk
prediction tool will help identify high-risk populations and guide management strategies at the transition
to dialysis.
ª 2018 Mayo Foundation for Medical Education and Research n Mayo Clin Proc. 2018;93(9):1224-1235T he number of incident cases ofend-stage renal disease (ESRD) in theUnited States has risen over time and
exceeded 120,000 in 2014.1 There is substan-
tial heterogeneity in the incident ESRD
population in which some patients may die
early after dialysis initiation while others may
experience greater longevity with dialysis.
Overall, mortality is exceptionally high during
the ﬁrst year of dialysis.1
Plans for the initiation of maintenance
dialysis therapy, including whether to initiateMayo Clin Proc. n September 2018;
www.mayoclinicproceedings.org ndialysis, integrate conservative care, or orga-
nize end-of-life support, are affected by
various factors such as comorbid conditions,
personal beliefs, and cultural perspectives.2,3
A risk prediction model to predict early mor-
tality could help individualize treatment and
support the shared decision-making process
among clinicians, patients, and patients’ family
members. For example, if a patient has high
anticipated risk of mortality within 1 year of
dialysis, conservative management with infre-
quent dialysis therapy could be a potential93(9):1224-1235 n https://doi.org/10.1016/j.mayocp.2018.04.017
ª 2018 Mayo Foundation for Medical Education and Research
85,505 Veterans transitioned to dialysis
          between 10/01/2007 and 03/31/2014
45,351 Excluded (no data on eGFR during
          12 mo before dialysis initiation)
40,154 Met eGFR criteria
36,585 Met diagnosis criteria
3569 Excluded (no ICD-9 code for
        renal disease diagnosis)
707 Excluded for missing cause of ESRD
35,878 Patients with ≥1 eGFR during 12 mo before dialysis
           initiation who had data on cause of ESRD and
           the ICD-9 codes for renal disease
24,030 Development
data set
11,848 Internal validation
data set
A
4284 External validation
data set
9700 KPSC patients transitioned to dialysis
        between 01/01/2007 and 09/30/2015
9103 Met eGFR criteria
8981 Met diagnosis criteria
597 Excluded (no data on eGFR during
      12 mo before dialysis initiation
122 Excluded (no ICD-9 code for
       renal disease diagnosis)
171 Excluded for missisng cause of ESRD
983 Excluded for unknown race or ethnicity
7827 Patients with ≥1 eGFR during 12 mo before dialysis
        initiation who had data on cause of ESRD and
        the ICD-9 codes for renal disease
3543 Excluded for missing data on any
        laboratory tests in the final model
B
FIGURE 1. Study ﬂowchart of the Veterans Affairs cohort (A) and the Kaiser Permanente Southern California (KPSC) cohort (B).
eGFR ¼ estimated glomerular ﬁltration rate; ESRD ¼ end-stage renal disease; ICD-9 ¼ International Classiﬁcation of Diseases, Ninth
Revision.
RISK SCORE AT TRANSITION TO DIALYSISoption.4-6 Additionally, it may provide little or
no beneﬁt but rather harm in such a case to
provide aggressive treatments for cancer or
certain chronic conditions such as hyperten-
sion, atrial ﬁbrillation, or hyperphosphatemia.
Several prediction models have been devel-
oped for patients among whom the decision to
implement dialysis has been already made.7-16
However, most of the previous models utilized
data obtained at the time of or after dialysis initi-
ation8-16 despite the fact that the shared decision-
making process regarding dialysis initiation
would sometimes require several weeks. Other
limitations of prior models include small sample
sizes,7-9 restriction of study populations to those
of elderly age,7,10-12 the use of less contemporary
cohorts (before 2005),8,9,12-14 lack of information
on race and/or ethnicity,7-9,11,12,16 and noncon-
sideration of readily available laboratory dataMayo Clin Proc. n September 2018;93(9):1224-1235 n https://doi.o
www.mayoclinicproceedings.orgsuch as serum albumin and/or estimated glomer-
ular ﬁltration rate (eGFR).7-9,11-16 Additionally,
model performance was not externally validated
in most cases.7-13,15
The aim of this study was to develop,
rigorously validate, and provide risk scores
to predict mortality during the ﬁrst year of
dialysis (ie, months 3, 6, 9, and 12) based
on pre-ESRD information among patients
who would transition to dialysis.PATIENTS AND METHODS
Study Population and Data Source
The Transition of Care in Chronic Kidney Disease
study included 2 historical cohorts with incident
ESRD: (1) 85,505 US veterans who transitioned
to dialysis treatment from October 1, 2007,
through March 31, 2014,17-20 and (2) 9700rg/10.1016/j.mayocp.2018.04.017 1225
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1226patients who transitioned to dialysis within the
Kaiser Permanente Southern California (KPSC)
health care system from January 1, 2007, through
September 30, 2015, both derived from the
United States Renal Data System (USRDS). In
the current study, we excluded patients without
data on eGFR during the 12 months before dial-
ysis initiation, those without the International
Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation (ICD-9-CM) codes for renal disease,
those with missing cause of ESRD, or unknown
race/ethnicity (Figure 1, A). We further restricted
patients in the KPSC cohort to those without
missing data on the variables selected in the ﬁnal
model (Figure 1, B). Differences in characteristics
between included vs excluded patients for each
cohort are summarized in Supplemental
Tables 1 and 2 (available online at http://www.
mayoclinicproceedings.org). This study was
approved by the institutional review boards of
the Memphis, Tennessee, and Long Beach,
California, Veterans Affairs (VA) Medical Centers
and KPSC. The requirement for written informed
consent was waived because of the large sample
size, patient anonymity, and nonintrusive nature
of the study.
Demographic Characteristics, Clinical Data,
and Laboratory Measurements
Baseline patient characteristics were drawn
from a composite of USRDS Patient and Medi-
cal Evidence ﬁles, Centers for Medicare and
Medicaid Services (CMS) databases, and the
respective administrative databases (ie, either
the VA or KPSC). Cause of ESRD was catego-
rized into 8 groups based on the ICD-9-CM
diagnosis codes indicated in the Medical
Evidence Report form CMS-2728
(Supplemental Table 3, available online at
http://www.mayoclinicproceedings.org). We
deﬁned pre-ESRD comorbidity status by the
ICD-9-CM diagnosis and surgical codes
recorded in both CMS and administrative
databases (Supplemental Table 4, available
online at http://www.mayoclinicproceedings.
org). Additionally, all patients with diabetes as
the cause of ESRD were considered to have
diabetes with complications. For comorbidities
with 2 levels (ie, diabetes [with vs without
complication], liver disease [mild vs moderate
or severe], and cancer [nonmetastatic vs meta-
static]), patients were considered to have only
the more severe condition if they had bothMayo Clin Proc. n September 2018;comorbidities. Ischemic heart disease included
myocardial infarction.
All data on body mass index and labora-
tory tests were obtained before dialysis initia-
tion. We calculated eGFR using the Chronic
Kidney Disease Epidemiology Collaboration
formula.21 The last measurement of each
variable before ESRD transition was used in
this study.
Statistical Analyses
Differences between groups were compared by
standardized differences because of the large
sample size of this study.22,23 Differences in
patient characteristics between 2 groups were
compared by standardized difference, of
which 0.8, 0.5, and 0.2 in absolute value
were considered large, medium, and small
differences, respectively.
Prediction models for mortality during the
ﬁrst year of dialysis were developed on the
basis of survival data up to 14 months after
transition to dialysis using Cox proportional
hazards models. Follow-up started at dialysis
initiation and continued until death or the
date of ﬁnal follow-up assessment (September
2, 2014). Information on date of censoring
events was obtained from the records of the
CMS, USRDS, and respective administrative
database. As candidate predictors, we a priori
selected clinically relevant variables less likely
to be intentionally modiﬁed (Table 1) and
excluded medications and easily modiﬁable
variables (ie, hemoglobin, potassium, calcium,
phosphorus, intact parathyroid hormone,
bicarbonate, ferritin, and lipids). The propor-
tions of missing data were approximately 3%
for body mass index, serum sodium, and
serum urea nitrogen and approximately 10%
for white blood cell, serum albumin, and
serum alkaline phosphatase. Missing data in
the VA cohort were imputed by their mean
values.
The VA cohort was randomly divided into a
two-thirds development set (n¼ 24,030) and a
one-third internal validation set (n ¼ 11,848).
Final models with reduced number of predic-
tors were obtained in the development data
set using backward selection based on Akaike
information criterion. To address potential
model overﬁtting (optimism), we estimated a
linear shrinkage factor (g) using 100 bootstrap
samples24-26 and adjusted the risk score by the93(9):1224-1235 n https://doi.org/10.1016/j.mayocp.2018.04.017
www.mayoclinicproceedings.org
TABLE 1. Pre-ESRD Characteristics of 35,878 Veterans Who Transitioned to Dialysis Therapy From October 1, 2007, through March 31, 2014,
Stratiﬁed by Last eGFR Measurement Before Dialysis Initiationa,b,c
Candidate predictors
Missing
frequency (%)
Total cohort
(N¼35,878)
Last eGFR (mL/min/1.73 m2)
Standardized
differenced
<15
(n¼22,605 [63%])
15
(n¼13,273 [37%])
Age (y) 0 69.411.1 67.811.2 72.210.4 0.41
Male 0 35,215 (98) 22,111 (98) 13,104 (99) 0.07
Race 0
White 24,344 (68) 14,123 (62) 10,221 (77) 0.32
Black 9913 (28) 7323 (32) 2590 (20) 0.30
Native American 204 (0.6) 145 (0.6) 59 (0.4) 0.03
Asian 196 (0.5) 135 (0.6) 61 (0.5) 0.02
Other 1221 (3) 879 (4) 342 (3) 0.07
Hispanic ethnicity 0 2474 (7) 1796 (8) 678 (5) 0.12
Cause of ESRD 0
Diabetes 17,182 (48) 11,098 (49) 6084 (46) 0.07
Hypertension/large-vessel disease 10,847 (30) 6791 (30) 4056 (31) 0.01
Primary glomerulonephritis 1766 (5) 1360 (6) 406 (3) 0.14
Interstitial nephritis/pyelonephritis 919 (3) 588 (3) 331 (2) 0.01
Neoplasms/tumors 886 (2) 478 (2) 408 (3) 0.06
Cystic/hereditary/congenital diseases 582 (2) 468 (2) 114 (0.9) 0.10
Secondary glomerulonephritis/vasculitis 295 (0.8) 189 (0.8) 106 (0.8) 0.00
Miscellaneous conditions 3401 (9) 1633 (7) 1768 (13) 0.20
Comorbidities (ICD-9-CM) 0
Renal disease 35,878 (100) 22,605 (100) 13,273 (100) 0.00
Hypertension 35,231 (98) 22,167 (98) 13,064 (98) 0.03
Hyperlipidemia 29,416 (82) 17,852 (79) 11,564 (87) 0.22
Anemia 26,481 (74) 16,404 (73) 10,077 (76) 0.08
Diabetes without complications 6577 (18) 4019 (18) 2558 (19) 0.04
Diabetes with complications 18,980 (53) 11,694 (52) 7286 (55) 0.06
Ischemic heart disease 21,234 (59) 11,527 (51) 9707 (73) 0.47
Myocardial infarction 9397 (26) 4491 (20) 4906 (37) 0.39
Congestive heart failure 19,870 (55) 10,462 (46) 9408 (71) 0.52
Atrial ﬁbrillation 5733 (16) 2530 (11) 3203 (24) 0.34
Peripheral vascular disease 13,773 (38) 7291 (32) 6482 (49) 0.34
Cerebrovascular disease 11,197 (31) 6088 (27) 5109 (38) 0.25
Depression 8980 (25) 5615 (25) 3365 (25) 0.01
Dementia 837 (2) 437 (2) 400 (3) 0.07
Chronic pulmonary disease 14,973 (42) 7653 (34) 7320 (55) 0.44
Mild liver disease 3128 (9) 1888 (8) 1240 (9) 0.03
Moderate or severe liver disease 776 (2) 330 (1) 446 (3) 0.12
Nonmetastatic cancer 7510 (21) 4367 (19) 3143 (24) 0.11
Metastatic carcinoma 806 (2) 379 (2) 427 (3) 0.10
Peptic ulcer disease 2363 (7) 1199 (5) 1164 (9) 0.14
Connective tissue disease/rheumatic disease 1345 (4) 677 (3) 668 (5) 0.10
Paraplegia/hemiplegia 1116 (3) 592 (3) 524 (4) 0.07
HIV/AIDS 361 (1) 267 (1) 94 (0.7) 0.05
Body mass index (kg/m2) 3 29.96.7 29.76.5 30.16.9 0.07
Last eGFR (mL/min/1.73 m2) 0 12.4 (8.6-18.6) 9.5 (7.2-11.9) 21.9 (17.6-30.7) 2.58
Laboratory tests
White blood cells (103/mL) 9 7.3 (5.9-9.0) 7.3 (5.9-9.1) 7.2 (5.8-8.9) 0.05
Serum sodium (mEq/L) 2 139.13.7 138.93.8 139.33.5 0.10
Serum albumin (g/dL) 9 3.40.6 3.30.6 3.50.6 0.21
Continued on next page
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TABLE 1. Continued
Candidate predictors
Missing
frequency (%)
Total cohort
(N¼35,878)
Last eGFR (mL/min/1.73 m2)
Standardized
differenced
<15
(n¼22,605 [63%])
15
(n¼13,273 [37%])
Laboratory tests, continued
Serum urea nitrogen (mg/dL) 4 6529 7527 4823 1.09
Serum alkaline phosphatase (IU/L) 11 82 (64-108) 80 (63-105) 86 (67-115) 0.19
aeGFR ¼ estimated glomerular ﬁltration rate; ESRD ¼ end-stage renal disease; HIV ¼ human immunodeﬁciency virus; ICD-9-CM ¼ International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation; IQR ¼ interquartile range.
bValues are presented as mean  SD, median (IQR), or No. (percentage). Percentages may not total 100 because of rounding.
cSI conversion factors: To convert white blood cell values to 109/L, multiply by 0.001; to convert sodium values to mmol/L, multiply by 1.0; to convert albumin values to
g/dL, multiply by 10; to convert urea nitrogen values to mmol/L, multiply by 0.357; to convert alkaline phosphatase values to mkat/L, multiply by 0.0167.
dDifferences in patient characteristics between 2 groups were compared by standardized difference, of which 0.8, 0.5, and 0.2 in absolute value were considered large,
medium, and small differences, respectively.
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1228shrinkage factor. Overﬁtting, particularly in
small data sets, results in regression coefﬁcients
being overestimated (overﬁtted) for prediction.
Thus, a shrinkage factor (0  g  1) is esti-
mated and applied to the risk score to shrink
the regression coefﬁcients towards zero so that
predictions will more likely show better calibra-
tion on new patients (ie, validation data).
Furthermore, our study has 2 additional pro-
tections against overﬁtting, ie, internal and
external validation cohorts.
Model calibration was assessed by calibra-
tion plots and a group-based goodness-of-ﬁt
test for survival model.27 In both the internal
and external validation data sets, model pre-
dictive discrimination was assessed using the
index of concordance, or C statistic.25
The ﬁnal prediction models based on the
shrunken prognostic score (PS) can be used
to estimate the predicted probabilities of
all-cause death at a given time t (month).
That is, the shrunken PS* that will be used
to predict the outcomes of new/future pa-
tients will be PS* ¼ g  b, where b is the
collection of estimated coefﬁcients in the ﬁnal
prediction model. The predicted survival at
time t for a new patient can be obtained as
S0(t)
exp(PS*), where S0(t) is the baseline
survival estimate from the ﬁnal model.
Kaplan-Meier survival estimates were
compared with predicted mortality at months
3, 6, 9, and 12 across 5 risk score categories
based on cutoff points at 5th, 35th, 65th, and
95th percentiles in respective eGFR groups of
the internal validation cohort. However,
predicted survival rates and their 95% CIs
were not provided for the external validationMayo Clin Proc. n September 2018;cohort due to data conﬁdentiality because it
required merging of the VA and KPSC data
at the individual level.
Analyses were performed in SAS version 9.3
PROC PHREG (SAS Institute) and R version
3.12 (R Project for Statistical Computing) using
libraries RMS and SURVIVAL.RESULTS
Baseline Characteristics of the VA Cohort
The 35,878 patients in the VA cohort had a
mean (SD) age of 69.411.1 years, 35,215
(98%) were male, 24,344 (68%) were white,
2474 (7%) were Hispanic, and 17,182 (48%)
had diabetes as the cause of their ESRD
(Table 1). The last eGFR before dialysis initia-
tion was 12.4 mL/min per 1.73 m2 (interquar-
tile range [IQR], 8.6-18.6 mL/min per 1.73
m2), and the prevalence of low and high
eGFR (ie, <15 or 15 mL/min per 1.73 m2)
were 63% (n¼22,605) and 37% (n¼13,273),
respectively. When compared with patients
with low eGFR, those with high eGFR were
older, more likely to be white, and more likely
to have a history of hyperlipidemia, cardiovas-
cular disease, and chronic pulmonary disease
(absolute standardized difference, >0.2).
There were no meaningful differences between
the development and internal validation data
sets (Supplemental Table 5, available online
at http://www.mayoclinicproceedings.org).
The time from the last eGFR measurement to
dialysis initiation was 24 days (IQR, 3-109
days). The prevalence of hemodialysis and
peritoneal dialysis as the initial dialysis
modality was 94% (11,162) and 5% (579),93(9):1224-1235 n https://doi.org/10.1016/j.mayocp.2018.04.017
www.mayoclinicproceedings.org
RISK SCORE AT TRANSITION TO DIALYSISrespectively, and dialysis modality was uncer-
tain among 107 patients (1%). There were a
total of 9813 deaths (4525 and 5288 deaths
among patients with low and high eGFR,
respectively) during the median follow-up of
14 months (IQR, 9-14 months). Six-month
and 1-year mortality rates were 10% and
18% among patients with low eGFR,
respectively, and 25% and 37% among
patients with high eGFR, respectively.
Development of the Prediction Score
A single prediction score resulted in poor
model ﬁt (P<.001 for goodness-of-ﬁt test).
We then evaluated model ﬁt by stratifying pa-
tients according to age, race, diabetes as the
cause of ESRD, initial dialysis modality, and
time from the last eGFR measurement to dial-
ysis initiation, and only stratiﬁcation based on
the last eGFR resulted in signiﬁcant improve-
ment (P>.1 for goodness-of-ﬁt test)
(Supplemental Table 6, available online at
http://www.mayoclinicproceedings.org). This
led to the development of 2 separate predic-
tion scores for patients stratiﬁed by low and
high eGFR. The ﬁnal early mortality prediction
model coefﬁcients are presented in Table 2.
The performances of our reduced/simpliﬁed
models as quantiﬁed by C statistics were prac-
tically the same as the full models (data not
shown).
Supplemental Figure 1, A and B (available
online at http://www.mayoclinicproceedings.
org) shows the predicted probability of 1-year
mortality after transitioning to dialysis as a func-
tion of risk score (ie, risk plots). Calibration plots
comparing observed vs predicted 1-year survival
graphically exhibited consistent results
(Supplemental Figure 2, A and B, available on-
line at http://www.mayoclinicproceedings.org).
We also compared Kaplan-Meier estimates and
predicted survival at months 3, 6, 9, and 12 after
dialysis initiation across 5 categories with cutoff
points at 5th, 35th, 65th, and 95th percentiles
of risk score in respective eGFR groups
(Figure 2, A and B). Predicted survival was
slightly lower than actual in the lowest-risk
group but was otherwise consistent (well cali-
brated) with the observed survival.
Internal Validation Within the VA Cohort
The performance of the prediction score was
tested in the internal validation data set ofMayo Clin Proc. n September 2018;93(9):1224-1235 n https://doi.o
www.mayoclinicproceedings.org11,848 veterans. The model discrimination
was acceptable among patients with low
eGFR, with a C statistic of 0.71 (95% CI,
0.70-0.72). The prediction model showed a C
statistic of 0.66 (95% CI, 0.65-0.67) among
those with high eGFR. Subgroup analyses
including initial dialysismodality (ie, hemodial-
ysis vs peritoneal dialysis) showed consistent C
statistics except for patients aged 65 years or
older, in whom C statistics were 0.66 (95%
CI, 0.65-0.68) and 0.63 (95% CI, 0.61-0.64)
for those with low and high eGFR, respectively
(Table 3). Risk plots are shown in Supplemental
Figure 1, C and D.
The group-based goodness-of-ﬁt tests
showed no signiﬁcant difference between
observed and predicted 1-year mortality after
transitioning to dialysis in both the low and
high eGFR groups (overall P>.1)
(Supplemental Table 6). Calibration plots
exhibited consistent results (Supplemental
Figure 2, C and D). Predicted vs observed
Kaplan-Meier estimates were also consistent, as
were those in the development cohort
(Figure 2, C and D).
External Validation
Compared with the VA cohort (n ¼ 35,8780),
the KPSC cohort (n ¼ 4284) was younger
(6514 years vs 6911 years) and included
more women (43% [1842] vs 2% [663]),
more Asians (11% [487] vs 0.5% [196]), and
more Hispanics (30% [1298] vs 7% [2474])
(Supplemental Table 7, available online at
http://www.mayoclinicproceedings.org). The
last eGFR before dialysis initiation in the
KPSC cohort was 10.5 mL/min per 1.73 m2
(IQR, 7.7-14.1 mL/min per 1.73 m2), and
the prevalence of low and high eGFR (<15
or 15 mL/min per 1.73 m2) was 79%
(3363) and 21% (921), respectively. Time
from the last eGFR measurement to dialysis
initiation was 11 days (IQR, 5-25 days), and
the prevalence of hemodialysis and peritoneal
dialysis as the initial dialysis modality was
87% (3727) and 13% (557), respectively.
Supplemental Table 8 summarizes data on
predictors in the ﬁnal model stratifying KPSC
patients by sex and last eGFR before dialysis
initiation. There were a total of 824 deaths
(552 and 272 deaths among patients with
low and high eGFR, respectively) during the
median follow-up time of 14 months (IQR,rg/10.1016/j.mayocp.2018.04.017 1229
TABLE 2. Cox Regression Model for Predicting Mortality Among Patients With Low and High eGFR at the Last Measurement Before Dialysis
Initiationa
Variable
Last eGFR
Low (<15 mL/min/1.73 m2) High (15 mL/min/1.73 m2)
Parameterb HR (95% CI) P value Parameterb HR (95% CI) P value
Age (per year) 0.0311 1.03 (1.03-1.04) <.001 0.0343 1.03 (1.03-1.04) <.001
Race
White Reference Reference
Black 0.4019 0.67 (0.61-0.73) <.001 0.2178 0.80 (0.73-0.89) <.001
Asian 0.6334 0.53 (0.29-0.96) .04 0.8342 0.43 (0.23-0.81) .009
Native American 0.4859 0.61 (0.36-1.04) .07 0.6384 0.53 (0.27-1.02) .06
Other 0.3692 0.69 (0.55-0.87) .002 0.2437 0.78 (0.60-1.02) .07
Hispanic ethnicity 0.2926 0.75 (0.64-0.87) <.001 0.2547 0.78 (0.64-0.93) .007
Cause of ESRD
Diabetes 0.3607 1.43 (1.18-1.74) <.001 0.3493 1.42 (1.12-1.79) .003
Hypertension/large-vessel disease 0.4261 1.53 (1.26-1.87) <.001 0.3428 1.41 (1.11-1.78) .004
Primary glomerulonephritis Reference Reference
Interstitial nephritis/pyelonephritis 0.5392 1.71 (1.30-2.26) <.001 0.5632 1.76 (1.30-2.37) <.001
Neoplasms/tumors 0.8410 2.32 (1.78-3.01) <.001 0.4618 1.59 (1.18-2.13) .002
Cystic/hereditary/congenital diseases 0.0997 0.91 (0.59-1.40) .66 0.5306 0.59 (0.32-1.08) .09
Secondary glomerulonephritis/vasculitis 0.3890 1.48 (0.97-2.25) .07 0.3876 1.47 (0.95-2.27) .08
Miscellaneous conditions 0.7526 2.12 (1.71-2.63) <.001 0.4874 1.63 (1.28-2.07) <.001
Comorbidities
Hyperlipidemia 0.1485 0.86 (0.78-0.95) .002 0.1886 0.83 (0.74-0.92) .001
Diabetes without complications Not selected 0.1191 1.13 (1.04-1.22) .004
Ischemic heart disease Not selected 0.1912 1.21 (1.10-1.33) <.001
Myocardial infarction 0.1555 1.17 (1.07-1.27) <.001 Not selected
Congestive heart failure 0.2273 1.25 (1.16-1.36) <.001 0.2353 1.27 (1.15-1.39) <.001
Atrial ﬁbrillation 0.2013 1.22 (1.11-1.35) <.001 0.1835 1.20 (1.11-1.30) <.001
Peripheral vascular disease 0.1251 1.13 (1.05-1.23) .002 Not selected
Cerebrovascular disease 0.1727 1.19 (1.10-1.29) <.001 0.1035 1.11 (1.03-1.19) .004
Dementia 0.4246 1.53 (1.27-1.85) <.001 Not selected
Chronic pulmonary disease 0.1796 1.20 (1.11-1.29) <.001 0.1482 1.16 (1.08-1.25) <.001
Moderate or severe liver disease 0.7509 2.12 (1.70-2.64) <.001 0.5212 1.68 (1.44-1.97) <.001
Metastatic carcinoma 0.7012 2.02 (1.68-2.43) <.001 0.2675 1.31 (1.12-1.53) .001
Body mass index (per kg/m2)c 0.0304 0.97 (0.96-0.98) <.001 0.0233 0.98 (0.97-0.98) <.001
Last eGFR (per mL/min/1.73 m2)c 0.0308 1.03 (1.02-1.05) <.001 0.0163 1.02 (1.01-1.02) <.001
Laboratory tests
White blood cells (per 103/mL) 0.0269 1.03 (1.02-1.04) <.001 Not selected
Serum albumin (per g/dL) 0.4381 0.65 (0.61-0.68) <.001 0.2610 0.77 (0.73-0.82) <.001
Serum urea nitrogen (per mg/dL) 0.0025 1.00 (1.00-1.00) .001 0.0057 1.01 (1.00-1.01) <.001
Serum sodium (per mEq/L) 0.0327 0.97 (0.96-0.98) <.001 0.0331 0.97 (0.96-0.98) <.001
Serum alkaline phosphatase (per IU/L) 0.0010 1.00 (1.00-1.00) <.001 0.0012 1.00 (1.00-1.00) <.001
aeGFR ¼ estimated glomerular ﬁltration rate; ESRD ¼ end-stage renal disease; HR ¼ hazard ratio.
bModel parameter estimate before application of shrinkage factor (ie, 0.970 and 0.965 for low and high eGFR groups, respectively). Estimated 1-year survival probabilities can
be obtained as: 1  S0exp(PS*), where PS* ¼ g  LP, g is the shrinkage factor, LP is the linear predictor using the given parameter estimates, and S0(t). S0(t) is the baseline
survival estimate from the ﬁnal model. S0 at months 3, 6, 9, and 12 were 0.9722, 0.9446, 0.9234, and 0.9011 for patients with last eGFR <15 mL/min/1.73 m
2, respectively,
and 0.9313, 0.8790, 0.8369, and 0.7994 for patients with last eGFR 15 mL/min/1.73 m2, respectively.
cLast available value during 1 year before dialysis initiation.
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123014-14 months). Six-month and 1-year mortal-
ity were 9% and 15% among patients with low
eGFR, respectively, and 20% and 29% among
patients with high eGFR, respectively.
Risk plots for the KPSC cohort show the
same pattern of relationship between mortalityMayo Clin Proc. n September 2018;and risk score (Supplemental Figure 1, E
and F). However, observed survival was
typically higher than model-predicted sur-
vival, especially in the high-risk groups
(Supplemental Figure 2, E and F). Neverthe-
less, the Kaplan-Meier estimates (Figure 2, E93(9):1224-1235 n https://doi.org/10.1016/j.mayocp.2018.04.017
www.mayoclinicproceedings.org
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FIGURE 2. Observed survival curves during the ﬁrst year of dialysis and predicted survival at months 3, 6, 9, and 12 across 5 risk score
categories in patients with last estimated glomerular ﬁltration rate (eGFR) before initiation of dialysis of less than 15 mL/min per 1.73
m2 or 15 mL/min per 1.73 m2 or greater in the development Veterans Affairs (VA) cohort (A and B), the internal validation VA
cohort (C and D), and the external validation Kaiser Permanente Southern California (KPSC) cohort (E and F), respectively. Survival
curves (solid lines) were based on Kaplan-Meier (KM) estimates. Points and bars represent means and 95% CIs of predicted survival
for the risk score categories. Cutoff points were selected at 5th, 35th, 65th, and 95th percentiles in respective eGFR groups of the
internal validation cohort and were consistent across cohorts. Predicted survival rates and their 95% CIs were not provided for the
external validation cohort due to data conﬁdentiality because it requires merging of the VA and KPSC data at the individual level.
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TABLE 3. Overall and Subgroup Analyses of Discrimination Performance as Quantiﬁed by C Statistics in the
11,848. Patients in the Internal Validation Veterans Affairs Cohorta
Subgroup
Last eGFR <15 mL/min/1.73 m2 Last eGFR 15 mL/min/1.73 m2
No. of patients Median (95% CI) No. of patients Median (95% CI)
Overall 7463 0.71 (0.70-0.72) 4385 0.66 (0.65-0.67)
Age (y)
<65 3317 0.70 (0.68-0.73) 1209 0.69 (0.66-0.72)
65 4146 0.66 (0.65-0.68) 3176 0.63 (0.61-0.64)
Race
White 4697 0.69 (0.67-0.70) 3375 0.64 (0.63-0.66)
Other 2766 0.71 (0.68-0.73) 1010 0.69 (0.67-0.72)
Cause of ESRD
Diabetes 3677 0.70 (0.68-0.72) 2031 0.68 (0.66-0.70)
Hypertension 2202 0.71 (0.69-0.73) 1338 0.64 (0.62-0.66)
GN/CKD/IN/PN 810 0.70 (0.66-0.74) 260 0.68 (0.63-0.73)
Other 774 0.69 (0.66-0.73) 756 0.62 (0.59-0.65)
Initial dialysis modalityb
Hemodialysis 6977 0.71 (0.69-0.72) 4185 0.66 (0.64-0.67)
Peritoneal dialysis 421 0.74 (0.67-0.80) 158 0.72 (0.65-0.79)
Time from last visit to dialysis
initiation (mo)
<6 7098 0.71 (0.69-0.72) 3276 0.66 (0.65-0.68)
6-12 365 0.70 (0.65-0.75) 1109 0.66 (0.63-0.68)
aeGFR ¼ estimated glomerular ﬁltration rate; ESRD ¼ end-stage renal disease; GN ¼ glomerular nephritis; CKD ¼ cystic kidney disease;
IN ¼ interstitial nephritis; PN ¼ pyelonephritis.
bInitial dialysis modality was uncertain among 65 and 42 patients with last eGFR <15 and >¼15 ml/min/1.73m2, respectively, and they
were excluded in the subgroup analyses based on initial dialysis modality due to small sample sizes.
MAYO CLINIC PROCEEDINGS
1232and F) show the same consistent ordering of
survival and risk score percentile (ie, high
risk score, high mortality), and the prediction
score showed similar or even better discrimi-
nation in the KPSC cohort than in the VA
cohort; C statistics were 0.77 (95% CI, 0.74-
0.79) and 0.74 (95% CI, 0.71-0.76) among
men and women with low eGFR, respectively,
and 0.71 (95% CI, 0.67-0.74) and 0.67 (95%
CI, 0.62-0.72) among men and women with
high eGFR, respectively.
DISCUSSION
In this study, we developed a prediction tool for
mortality during the ﬁrst year of dialysis based
on pre-ESRD data in a large contemporary na-
tional cohort of US veterans. Although the VA
cohort has inherently unique characteristics
compared with other populations, these new
risk scores appeared generalizable given that
these were externally validated in the racially,
ethnically, and gender diverse KPSC cohort
with reasonable discrimination in most studies
groups. In order to facilitate practical imple-
mentation, we have created an online risk score
calculator at www.DialysisScore.com thatMayo Clin Proc. n September 2018;provides the predicted risk of mortality at
months 3, 6, 9, and 12 after dialysis initiation.
The discriminatory performance of our risk
score may be improved by adding other factors
such as socioeconomic status,28 medication
adherence,29 and timing of referral to nephrol-
ogists.30,31 In particular, physical and cognitive
function may play an important role in predict-
ing outcomes among elderly patients, in whom
our risk score showed C statistics of less than
0.7. Indeed, geriatric syndromes such as cogni-
tive impairment and frailty are prevalent in
the dialysis population,32 and the decline in
cognitive and physical function has been
shown to accelerate after dialysis initiation,
especially among elderly patients.33-35 These
variables are difﬁcult to capture because trained
personnel and careful consideration are neces-
sary for their evaluation, but comprehensive
risk models accounting for additional measures
speciﬁc to the elderly population may help
predict mortality more precisely.
Several previous prediction models focused
on the elderly population7,10-12 given the differ-
ences in clinical consequences (eg, high mortal-
ity and hospitalization rates) and patient93(9):1224-1235 n https://doi.org/10.1016/j.mayocp.2018.04.017
www.mayoclinicproceedings.org
RISK SCORE AT TRANSITION TO DIALYSIScharacteristics (eg, more severe comorbid condi-
tions and dialysis initiation with higher eGFR)
among older patients.36,37 However, we
obtained satisfactory model ﬁt with stratiﬁcation
by last eGFR before dialysis initiation but not
with stratiﬁcation by age (data not shown), sug-
gesting that the association between risk factors
and outcomes is dependent on comorbid condi-
tions rather than age. Higher eGFR may reﬂect
unmeasured clinical conditions at the time of
dialysis initiation, such as severely impaired car-
diac function requiringmore strict ﬂuidmanage-
ment than usual and overestimation of actual
kidney function due to lowmusclemass. Indeed,
the increased mortality risk associated with
higher eGFR in our study was consistent with
that in previous studies,7 and these heteroge-
neous conditions may explain why model ﬁt
was improved by stratiﬁcation according to last
eGFR and why we observed lower C statistics
among patients with high eGFR.
The patterns of mortality during the ﬁrst
year of dialysis have been reported to differ by
age and treatment modality.1 For patients
undergoing hemodialysis, mortality is espe-
cially high during the ﬁrst several months,
and this early mortality is more remarkable
among older patients. In contrast, patients un-
dergoing peritoneal dialysis have relatively con-
stant mortality over the course of the year.
Nevertheless, a previous study reported similar
outcomes between dialysis modalities when ac-
counting for patient characteristics,38 and our
risk scores had consistent C statistics across
subgroups of age and treatment modality
(Table 3). Predicted survival was also concor-
dant with observed survival across risk groups
and time points except for month 6 in the high-
est risk score group (ie,95th percentile of risk
score) among patients with a last eGFR of 15
mL/min per 1.73 m2 or higher (Figure 2).
This group was the oldest population, and their
overestimated survival may be explained by the
early mortality phenomena among the elderly.
Our study results should be interpreted
with several potential limitations in mind.
First, the model performance may depend on
the accuracy of data on comorbid conditions.
We used speciﬁc ICD-9-CM codes in the
CMS and administrative databases but were
not able to conﬁrm their accuracy. However,
our prediction model was externally validated
in the KPSC cohort where clinical practice isMayo Clin Proc. n September 2018;93(9):1224-1235 n https://doi.o
www.mayoclinicproceedings.orgdifferent from that of the VA, suggesting little
impact of this potential bias. Furthermore, by
using diagnostic codes to identify the presence
of comorbid conditions, our score lends itself
to automated implementation in electronic
medical records. Second, although prediction
performances (C statistics) were similar for
the development and internal validation for
the VA cohort as well as the external KPSC
cohort, overall calibration was better for the
interval validation cohort (Supplemental
Figure 2) as expected because of the survival
differences in the KPSC and VA cohorts.
Future model reﬁnements may include a
mixture of patient cohorts more representative
of the general dialysis population. Third,
timing to use this risk score would also affect
the model performance because values in
selected variables change over time. Although
C statistics were consistent between veterans
with different time periods between the last
eGFR measurement and dialysis initiation (ie,
<6 vs 6 months) (Table 3), our model
showed greater discrimination in the lower
eGFR groups and the KPSC cohort, in whom
the lag period was shorter than that of
their counterparts. Fourth, our cohort con-
sisted mostly of whites and blacks. Although
the KPSC cohort included 11% Asians, pre-
dicted mortality should be interpreted with
caution in races other than whites or blacks
before being validated in a speciﬁc race. Lastly,
we did not account for vascular access.
However, several studies have found that the
mortality risk associated with vascular access
may largely be accounted for by patient
characteristics.39,40CONCLUSION
A new prediction tool for mortality during the
ﬁrst year of dialysis was developed and
externally validated among incident dialysis
patients in the United States. This tool is avail-
able at our website www.DialysisScore.com,
which allows clinicians, patients, and patient
family members to obtain the predicted mor-
tality at months 3, 6, 9, and 12 after dialysis
initiation. Our new tool could help improve
nephrology care and may facilitate shared
decision making for individualized prepara-
tion for dialysis initiation in late stages of
chronic kidney disease.rg/10.1016/j.mayocp.2018.04.017 1233
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